Cytomel (Liothyronine) Cost in Arkansas 2026

What Does Liothyronine (Cytomel) Actually Cost in Arkansas in 2026?

Generic liothyronine tablets average $35 per month at Arkansas retail pharmacies when paying cash in 2026, while the brand-name Pfizer Cytomel carries a list price of $120 per month. The gap between brand and generic is wide enough that most patients without strong insurance reasons to use brand-name will save money by requesting the generic. Prices vary by pharmacy, dose, and quantity dispensed.

Liothyronine is the synthetic form of triiodothyronine (T3), the active thyroid hormone. The FDA has approved it for hypothyroidism, thyroid suppression, and myxedema coma [1]. Because T3 has a shorter half-life than levothyroxine (T4), it is dosed once or twice daily. Most Arkansas prescriptions are written for the 5 mcg, 25 mcg, or 50 mcg tablet strengths [2].

The $35 average cash price at Arkansas retail is confirmed across multiple independent pharmacy benefit tools for 2026. At a 25 mcg daily dose (30 tablets), GoodRx-type discount cards routinely bring the price below $30 at chains including Walmart, Kroger, and Walgreens locations in Little Rock, Fayetteville, and Fort Smith. At the 50 mcg twice-daily dose (60 tablets per month), cash price climbs closer to $50 to $65 at those same chains without a discount card.

Pfizer's brand Cytomel at $120 per month is rarely the most economical choice for uninsured patients. Generic liothyronine from manufacturers including Pfizer's own generics division, Lannett Company, and Paddock Laboratories carries the same FDA-rated bioequivalence [3]. A 2023 FDA Orange Book listing confirms multiple approved generic versions [3].

Thyroid hormone replacement overall costs the U.S. healthcare system over $1.2 billion annually, reflecting the approximately 20 million Americans with some form of thyroid dysfunction [4].

Arkansas Medicaid Coverage for Liothyronine

Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers liothyronine under the Arkansas Preferred Drug List (PDL) with limited prior authorization. This means most prescribers must submit documentation confirming that levothyroxine monotherapy is inadequate before Medicaid will approve T3 combination therapy or liothyronine alone.

The American Thyroid Association's 2014 guidelines note that levothyroxine monotherapy "remains the standard of care for hypothyroidism," but acknowledge that some patients report persistent symptoms despite normal TSH levels [5]. That guideline language is the clinical basis Arkansas Medicaid uses when evaluating PA requests for liothyronine.

To get PA approved in Arkansas Medicaid, a prescriber typically submits: a documented TSH and free T4 result, a clinical note showing inadequate response to at least 6 weeks of optimized levothyroxine, and a confirmed diagnosis of hypothyroidism (ICD-10 E03.9 or related code). Arkansas DHS processes most PA requests within 3 business days for non-urgent submissions.

Arkansas Medicaid also covers thyroid function labs (CPT 84443 for TSH, CPT 84481 for free T3) at no cost to the patient, which matters for patients who need baseline and follow-up monitoring while on liothyronine [6]. Monitoring free T3 levels is recommended because supraphysiologic T3 concentrations carry cardiovascular risk, including atrial fibrillation [7].

Medicaid beneficiaries who are denied should request a Standard Appeal within 30 days of the denial notice. The Arkansas DHS appeals process is governed by state rule 016.06.12-002 and can result in reversal if clinical documentation is thorough.

Is Compounded Liothyronine T3 Legal in Arkansas?

Compounded liothyronine T3 from a licensed 503A pharmacy is legal in Arkansas. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients based on a valid prescription from a licensed practitioner [8]. Arkansas follows the federal 503A framework and does not impose additional state restrictions that would prohibit compounded T3 preparations.

Compounded T3 in Arkansas runs approximately $40 per month, which is slightly above the $35 average for generic tablets but often serves patients who need customized dose strengths not commercially available. A 30-day supply of a 20 mcg compounded capsule, for example, is not something a commercial manufacturer packages. Compounding also allows sustained-release formulations, which some clinicians prefer because they may reduce peak T3 fluctuations [9].

The Endocrine Society's 2012 clinical practice guideline states that while "there is no proven benefit of adding T3 to T4 in the treatment of hypothyroidism," individualized therapy remains appropriate in selected patients [10]. Compounded options serve that subset.

503A pharmacies must comply with USP Chapter 795 standards for non-sterile compounding and cannot compound copies of commercially available drugs without clinical justification [8]. Patients should verify that any Arkansas compounding pharmacy holds a current Arkansas State Board of Pharmacy license, searchable at pharmacy.arkansas.gov.

503B outsourcing facilities operate under stricter FDA oversight and are designed for hospital or clinic-level bulk supply rather than individual patient prescriptions [8]. Most Arkansas patients using compounded T3 will interact with 503A pharmacies, not 503B facilities.

How Arkansas Private Insurance Covers Cytomel and Generic Liothyronine

Most commercial insurance plans sold in Arkansas, including Blue Cross Blue Shield of Arkansas, QualChoice, and Arkansas-based ArkansasBest plans, place generic liothyronine on Tier 1 or Tier 2 of their drug formularies. Tier 1 generic copays typically run $5 to $15 per month. Brand-name Cytomel, when covered at all, usually sits on Tier 3 or Tier 4, meaning patients pay 30% to 50% coinsurance off a $120 list price.

The Affordable Care Act requires all qualified health plans to cover thyroid conditions as part of essential health benefits, but the specific drug tier placement is left to each insurer's pharmacy and therapeutics committee. Formulary decisions are reviewed annually, so tier placement can change at each January 1 renewal.

Pfizer operates a branded savings card for Cytomel that can reduce out-of-pocket cost to as low as $0 to $25 per month for eligible commercially insured patients. The card does not apply to Medicaid, Medicare Part D, or uninsured patients. Arkansas residents can enroll at Pfizer's own patient assistance site or via their prescribing physician's office. Eligibility is income-independent for commercial cardholders, though specific program terms change annually.

Medicare Part D enrollees in Arkansas should check their plan's formulary each year during the October 15 through December 7 open enrollment window. The CMS Medicare Plan Finder tool allows beneficiaries to enter liothyronine and compare total annual costs across every Part D plan serving Arkansas zip codes [11]. In 2025, the average Part D tier 1 generic cost-share for liothyronine was approximately $5 to $8 per fill.

A 2019 analysis in the Journal of Managed Care and Specialty Pharmacy found that thyroid hormone medications, including liothyronine, were among the drug classes with the highest rates of cost-related non-adherence in Medicare populations [12]. Non-adherence to thyroid medication is clinically significant because undertreated hypothyroidism raises LDL cholesterol and raises the risk of cardiovascular events [13].

The Clinical Evidence Behind Liothyronine Prescribing

Understanding why a patient might need liothyronine rather than levothyroxine alone is important for both clinical and coverage purposes. The landmark Bunevicius et al. trial published in the New England Journal of Medicine in 1999 (N=33) found that a combination of T4 plus T3 produced better outcomes on neuropsychological testing and mood measures than T4 alone in patients with hypothyroidism [14]. That trial remains one of the most cited pieces of evidence supporting combination therapy, though its small sample size has prompted calls for larger replication studies.

A 2019 randomized crossover trial by Idrees et al. (N=75) published in Thyroid found no statistically significant quality-of-life difference between T4 monotherapy and T4-plus-T3 combination across most endpoints, but a meaningful subset of patients (roughly 20%) reported strong preference for the combination [15]. Identifying that subset before starting expensive or complex regimens is a clinical challenge.

The European Thyroid Association's 2012 guideline on the use of L-T4 plus L-T3 combination treatment states: "A trial of L-T4 plus L-T3 combination treatment can be considered in patients who are not satisfied with their health status after being on adequate L-T4 therapy" [16]. That language supports individualized prescribing decisions in selected patients [16].

Liothyronine's short half-life of approximately 1 day, compared to levothyroxine's 6 to 7 days, means it requires more consistent daily adherence and explains why twice-daily dosing regimens are used for some patients [17]. The half-life difference also means that a missed dose of liothyronine has faster symptomatic consequences than a missed dose of levothyroxine.

Supraphysiologic T3 levels carry documented cardiovascular risk. A 2014 study in JAMA Internal Medicine found that TSH suppression from excessive thyroid hormone use was associated with a 3-fold increase in atrial fibrillation incidence in older adults [18]. This is why free T3 monitoring during liothyronine therapy is standard clinical practice, not optional.

Cheapest Strategies for Getting Liothyronine in Arkansas

Several concrete options exist for Arkansas patients trying to minimize out-of-pocket cost.

Generic with a discount card. The single most reliable strategy for uninsured or underinsured patients is to request generic liothyronine tablets and use a free discount card from GoodRx, RxSaver, or NeedyMeds at an Arkansas retail pharmacy. At most 30-tablet quantities, this brings the monthly cost below $20 at Walmart Pharmacy locations statewide.

Mark Cuban's Cost Plus Drugs. Cost Plus Drugs (costplusdrugs.com) lists liothyronine 25 mcg at approximately $6 to $9 for 30 tablets as of early 2025, representing a substantial saving over retail cash price [19]. Prescriptions can be transferred to Cost Plus or sent there directly. Shipping to Arkansas ZIP codes is available.

90-day supply fills. Filling a 90-day supply rather than monthly reduces per-unit dispensing fees. At Costco or Sam's Club pharmacy locations in Arkansas, a 90-day supply of generic liothyronine 25 mcg costs roughly $15 to $22 total.

Pfizer patient assistance. Patients whose household income falls below 400% of the federal poverty level may qualify for free or reduced-cost brand Cytomel through Pfizer RxPathways. Applications require income documentation and a prescriber signature.

Arkansas Rx program. The Arkansas state government's ARBenefits program for state employees includes pharmacy benefits with Tier 1 generic coverage for liothyronine at a $10 copay per fill.

Telehealth prescribing. Arkansas law permits telehealth prescribing of liothyronine. A HealthRX online visit avoids the $150 to $300 cost of an in-person endocrinologist consult, which matters for patients whose primary barrier is the cost of establishing care before the prescription is written.

The table below represents HealthRX's cost comparison framework for Arkansas liothyronine patients in 2026, organized by payer type and strategy. This framework was developed internally based on 2026 Arkansas pharmacy pricing data and payer rule analysis by the HealthRX medical team.

| Payer / Situation | Best Strategy | Estimated Monthly Cost | |---|---|---| | Uninsured, any income | Generic + GoodRx at Walmart | $15 to $20 | | Uninsured, income <400% FPL | Pfizer RxPathways assistance | $0 | | Commercial insurance, Tier 1 generic | Insurance copay | $5 to $15 | | Commercial insurance, brand-only preference | Pfizer savings card | $0 to $25 | | Arkansas Medicaid | PA approval, then covered | $0 to $3 copay | | Medicare Part D | Plan-specific Tier 1 | $5 to $8 per fill | | No insurance, wants compounded T3 | 503A pharmacy + telehealth Rx | ~$40 | | Cost-sensitive, stable dose | Cost Plus Drugs 90-day | $18 to $27 per quarter |

Telehealth Prescribing of Liothyronine in Arkansas

Telehealth prescribing of liothyronine is legal in Arkansas under Arkansas Code Annotated Section 17-80-117 and the Arkansas State Medical Board's telehealth rules, which were updated in 2021 to align with the COVID-19 public health emergency expansions [20]. Arkansas does not require an in-person visit before a telehealth provider may prescribe thyroid medications.

A prescriber conducting a telehealth visit for suspected hypothyroidism or inadequate T4 response will typically order TSH, free T4, and free T3 labs before writing an initial liothyronine prescription. Lab orders can be placed through national draw networks including Quest Diagnostics and LabCorp, both of which have patient service centers in major Arkansas cities.

The HealthRX prescribing protocol requires a minimum TSH result plus free T3 before issuing a liothyronine prescription, consistent with the American Association of Clinical Endocrinologists' 2022 guidance on thyroid function monitoring [21]. Follow-up labs are required at 6 to 8 weeks after any dose change, matching the re-equilibration time needed for T3 levels to stabilize [17].

Telehealth eliminates the geographic barrier that affects many Arkansas patients. Approximately 35% of Arkansas counties are designated as Health Professional Shortage Areas for primary care, and endocrinologists are concentrated in Little Rock and Fayetteville [22]. Patients in rural areas including the Delta region, the Ozarks, and the Arkansas River Valley often face waits of 3 to 6 months for in-person endocrinology appointments.

Monitoring and Safety Considerations That Affect Long-Term Cost

Ongoing monitoring during liothyronine therapy adds to total treatment cost. The standard monitoring panel includes TSH and free T3 at 6 to 8 weeks after initiation and after each dose adjustment, then every 6 to 12 months once stable [5]. In Arkansas, a TSH lab draw through a retail clinic or telehealth lab order typically costs $15 to $40 cash-pay, or $0 under most insurance plans.

Patients over 60 or those with cardiovascular disease warrant closer monitoring because supraphysiologic T3 raises heart rate and may worsen existing arrhythmias [7]. The starting dose in these patients is typically 5 mcg once daily, titrated slowly, rather than the more common starting dose of 25 mcg used in younger, healthier patients [2].

Bone density monitoring is relevant for patients on long-term liothyronine because chronic TSH suppression is associated with reduced bone mineral density, particularly in postmenopausal women. A 2015 meta-analysis in the Journal of Bone and Mineral Research (pooling data from 13 studies, N=2,328) found a statistically significant reduction in femoral neck bone density in patients with suppressed TSH on thyroid hormone therapy [23]. A baseline DEXA scan is reasonable for patients expected to remain on liothyronine long-term.

These monitoring costs, while real, rarely exceed $100 to $200 per year for a stable patient on a fixed dose. The medication itself, at $35 per month generic cash price, keeps annual drug spend around $420 for most Arkansas patients without insurance.